A new paper from MUSC Hollings Cancer Center researchers is helping to reveal the "rules" for engineering chimeric antigen receptor (CAR) Tregs. Tregs, or T-regulatory cells, have shown promise in ...

Tr1X, Inc. (pronounced “Trix”), a clinical-stage biopharmaceutical company developing first-in-class allogeneic engineered ...

Dr. Kean has engineered Tregs with CARs that recognize OX40L, a molecule on the surface of immune cells in people with active lupus. She will now test these “OX40L-CAR-Tregs" in human cells and ...

Tr1X, Inc. (pronounced “Trix”), a clinical-stage biopharmaceutical company developing first-in-class allogeneic engineered ...

Do you want to bring your CAR NK cell and Treg cell research into clinical applications? Watch this webinar and explore Miltenyi Biotec’s solutions to advance CAR NK cell and Treg-based therapies – ...

Dr. Kean has engineered Tregs with CARs that recognize OX40L, a molecule on the surface of immune cells in people with active lupus. She will now test these "OX40L-CAR-Tregs" in human cells and ...